Panel discussion on the treatment of patients with factor VIII inhibitors
Lusher, J.M.; Eyster, M.E.; Hilgartner, M.W.; Kasper, C.K.; Mannucci, P.M.; Nilsson, I.M.; Penner, J.A.; Roberts, H.R.
Progress in Clinical and Biological Research 150: 323-335
1984
ISSN/ISBN: 0361-7742 PMID: 6431437 Document Number: 236680
Document emailed within 1 workday
Related Documents
Kessler, C.M.; Ludlam, C.A. 1993: The treatment of acquired factor VIII inhibitors: worldwide experience with porcine factor VIII concentrate. International Acquired Hemophilia Study Group Seminars in Hematology 30(2 Suppl. 1): 22-27Brettler, D.B.; Forsberg, A.D.; Levine, P.H.; Aledort, L.M.; Hilgartner, M.W.; Kasper, C.K.; Lusher, J.M.; McMillan, C.; Roberts, H. 1989: The use of porcine factor VIII concentrate (Hyate:C) in the treatment of patients with inhibitor antibodies to factor VIII. A multicenter US experience Archives of Internal Medicine 149(6): 1381-1385
Johannessen, M.; Andreasen, R.B.; Nordfang, O. 2000: Decline of factor VIIi and factor IX inhibitors during long-term treatment with NovoSeven Blood Coagulation and Fibrinolysis: An International Journal in Haemostasis and Thrombosis 11(3): 239-242
Brettler, D.B. 1993: Inhibitors of factor VIII: detection and treatment Southeast Asian Journal of Tropical Medicine and Public Health 24(Suppl 1): 21-25
Green, D. 1994: Immunosuppression of patients with acquired factor VIIi inhibitors Seminars in Hematology 31(2 Suppl 4: 60-61
Mahasandana, C.; Suvatte, V.; Püng-amritt, P.; Tuchinda, S. 1979: Von Willebrand's disease: studies of platelet functions, factor VIII procoagulant activity (F VIII C) and factor VIII-related antigen (F VIII RAg) in three families Southeast Asian Journal of Tropical Medicine and Public Health 10(2): 243-247
Iizuka, A.; Kuwashima, M.; Nagao, T. 1982: Clinical effects of FEIBA on hemophilia patients with inhibitors to factor VIIi or IX Nihon Ketsueki Gakkai Zasshi: Journal of Japan Haematological Society 45(5): 987-992
Brown, J.E.; Carton, C.L.; Hougie, C. 1981: The effect of naturally occurring antibodies to factor VIIi on an immunoradiometric assay for factor VIIi coagulant antigen. Observation on a cross-reacting material-positive (CRM+) hemophiliac with a factor VIIi inhibit Journal of Laboratory and Clinical Medicine 97(1): 65-71
Ewing, N.P. 1990: Induction of immune tolerance with factor VIIi concentrate in patients with hemophilia a and inhibitors Progress in Clinical and Biological Research 324: 59-68
Aznar, J.A.; Jorquera, J.I.; Peiró, A.; Garcia, I. 1984: The importance of corticoids added to continued treatment with Factor VIIi concentrates in the suppression of inhibitors in haemophilia a Thrombosis and Haemostasis 51(2): 217-221
Lottenberg, R.; Kentro, T.B.; Kitchens, C.S. 1987: Acquired hemophilia. A natural history study of 16 patients with factor VIII inhibitors receiving little or no therapy Archives of Internal Medicine 147(6): 1077-1081
Teitel, J.M.; Lau, H.K.; Garvey, M.B. 2002: Discrepancies in measured factor VIIi activity in patients treated with factor VIIi concentrate of human or porcine origin Thrombosis and Haemostasis 88(1): 159-160
Hauser, I.; Schneider, B.; Lechner, K. 1995: Post-partum factor VIII inhibitors. A review of the literature with special reference to the value of steroid and immunosuppressive treatment Thrombosis and Haemostasis 73(1): 1-5
Hay, C.R.; Colvin, B.T.; Ludlam, C.A.; Hill, F.G.; Preston, F.E. 1996: Recommendations for the treatment of factor VIII inhibitors: from the UK Haemophilia Centre Directors' Organisation Inhibitor Working Party Blood Coagulation and Fibrinolysis: An International Journal in Haemostasis and Thrombosis 7(2): 134-138
Takahashi, I.; Furuta, M.; Mizuno, S.; Takamatsu, J.; Kamiya, T. 1993: Effect of substrate and diluent for factor VIIi activity in highly purified factor VIIi concentrate and patient plasma infused factor VIIi concentrate Rinsho Byori. Japanese Journal of Clinical Pathology 41(7): 825-830
Gatti, L.; Mannucci, P.M. 1984: Use of porcine factor VIII in the management of seventeen patients with factor VIII antibodies Thrombosis and Haemostasis 51(3): 379-384
Muntean, W. 1984: Purified complex of factor VIII coagulant moiety and phospholipid: high factor VIII coagulant activity in factor VIII inhibitor plasma Wiener Klinische Wochenschrift 96(22): 829-832
Mahasandana, C.; Patharathienskul, D.; Suvatte, V. 1993: Hemophilia with factor VIII and factor IX inhibitors, incidence, bleeding problems and management Southeast Asian Journal of Tropical Medicine and Public Health 24(Suppl 1): 106-112
Hay, C.R.; Lozier, J.N.; Lee, C.A.; Laffan, M.; Tradati, F.; Santagostino, E.; Ciavarella, N.; Schiavoni, M.; Fukui, H.; Yoshioka, A.; Teitel, J.; Mannucci, P.M.; Kasper, C.K. 1996: Safety profile of porcine factor VIII and its use as hospital and home-therapy for patients with haemophilia-A and inhibitors: the results of an international survey Thrombosis and Haemostasis 75(1): 25-29
Watts, R.W.; Kelley, W.N.; Rapado, A.; Scott, J.T.; Seegmiller, J.E.; de Vries, A.; Wyngaarden, J.B.; Zöllner, N. 1977: Panel discussion: hyperuricemia as a risk factor Advances in Experimental Medicine and Biology 76b: 342-364